The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome
- PDF / 311,691 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 160 Views
ORIGINAL PAPER
The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome Ming Wu • Ding-yang Liu • Xian-rui Yuan Qing Liu • Xin-jun Jiang • Dun Yuan • Jun Huang • Xue-jun Li • Zhi-quan Yang
•
Received: 22 August 2012 / Accepted: 13 September 2012 Ó Springer Science+Business Media New York 2013
Abstract Moesin, a member of the ERM family, acts as a linker between the actin cytoskeleton and the plasma membrane and plays a key role in the control of cell morphology, motility, adhesion and other processes of tumourigenesis. The expression pattern and clinical significance of moesin in astrocytoma remain unknown. In this study, we used RT-PCR to systematically investigate the expression of moesin in 49 astrocytomas of different pathological grade and 6 normal brain tissues. We found that the mRNA expression levels of moesin in astrocytomas were significantly higher in comparison with normal brain tissues. Furthermore, moesin up-regulation was correlated with pathological grade of astrocytomas. Subsequently, we tested 112 astrocytomas and 14 normal brain tissues by immunohistochemistry. Similar results were also confirmed. Univariate and multivariate survival analysis were used to determine the correlations of moesin expression with overall survival and progression-free survival. Our results showed the expression of moesin was strongly negatively correlated with the patient progressionfree survival and overall survival. These results suggest moesin protein involved in the genesis and progression of astrocytomas and might be regarded as an independent predictor of poor prognosis. Keywords
Moesin Astrocytoma Prognosis factor
Ming Wu and Ding-yang Liu contributed equally. M. Wu D. Liu X. Yuan Q. Liu X. Jiang D. Yuan J. Huang X. Li Z. Yang (&) Department of Neurosurgery, Xiangya Hospital, Central South University; The Institute of Skull Base Surgery and Neurooncology at Hunan, 87 Xiangya Road, Changsha 410008, Hunan, China e-mail: [email protected]
Background Astrocytomas, the most common primary tumors of the central nervous system, constitute approximately one-third of intrinsic neoplasms of the central nervous system (CNS). Despite recent advances in diagnosis and multimodality therapies such as surgery, radiation, chemotherapy and immunotherapy, the treatment of astrocytomas still constitutes a big challenge to neurosurgeons, and substantial improvement in the survival of patients with high-grade astrocytoma has not been achieved [1, 2]. Recurrence and progression and even a subsequent increase in malignancy largely account for the poor prognosis. These processes are mediated by many complex pathways and various regulatory molecules as well as the microenvironments [3]. So the molecular mechanisms of progression and treatment strategies targeting critical components of astrocytoma have stimulated wide interest. ERM proteins (ezrin/radixin/moesin), part of 4.1 superfamily, are found in high levels of actin-rich surface structures such as microvilli, f
Data Loading...
